VivoSeq
Other

Seroma

1

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Seroma is an early-stage landscape with 1 program across 1 company. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Withdrawn1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

Doxycycline Versus Standard Care to Prevent Seroma Formation
Withdrawn·NNorthwell Health·N/A·NCT01188954
The Role of Doxycycline in the Management of Postoperative Seromas: A Pilot Study
Recruiting·UUniversity of Miami·Phase 2·NCT07498010·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)